We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Pompe disease

News List

Nexviazyme® improves respiration and mobility long-term in Pompe disease patients EuropeanPharmaceuticalReview
February 11, 2022
Two-year data shows Pompe disease patients treated with Nexviazyme® (avalglucosidase alfa) have sustained improvements in respiratory function and mobility.
Enzyme Replacement Therapy Approved for Late-Onset Pompe Disease drugs
August 11, 2021
Nexviazyme (avalglucosidase alfa-ngpt) was approved for the treatment of the rare inherited disorder late-onset Pompe disease in patients 1 year of age and older, the U.S. Food and Drug Administration announced Friday.
US FDA approves Nexviazyme for late-onset Pompe disease expresspharma
August 09, 2021
The approval is based on the positive phase-III data demonstrating improvements in key disease burden measures and establishing its safety profile.
FDA Approves Nexviazyme (avalglucosidase alfa-ngpt) for Late-Onset Pompe Disease drugs
August 09, 2021
The U.S. Food and Drug Administration (FDA) has approved Nexviazyme (avalglucosidase alfa-ngpt) for the treatment of patients one year of age and older with late-onset Pompe disease, a progressive and debilitating muscle disorder.